单倍体移植治疗移植时存在MRD的急性髓系白血病患者
该研究评估了移植前疾病状态对143例接受氟达拉滨-美法仑(FM)预处理和移植后环磷酰胺(PTCy)单倍体移植(haplo-SCT)的急性髓系白血病(AML)患者移植结局的影响。中位随访29个月,全部患者2年无进展生存(PFS)率为41%。与移植时完全缓解(CR)患者相比,活动性疾病(n=29)和CR但血细胞计数未完全恢复(CRi)(n=39)患者PFS更差。在CR患者中,MRD阳性(n=24)与MRD阴性(n=41)患者的PFS无差异。
要点
- 移植时活动性疾病或CRi状态与haplo-SCT后PFS较差相关。
- 在CR患者中,移植时MRD状态不影响PFS。
- MRD阳性患者可能受益于尽快进行haplo-SCT。
核心结论
- 采用FM预处理和PTCy预防GVHD的haplo-SCT可能消除AML患者MRD阳性对移植结局的不良影响。
研究设计与样本
- 回顾性评估143例接受haplo-SCT的AML患者,采用FM预处理和PTCy预防GVHD。
主要发现
- 中位随访29个月,全部患者2年PFS率为41%。
- 与移植时CR患者相比,活动性疾病患者PFS的HR为3.5(95% CI: 2.05-6.1; P < .001)。
- 与移植时CR患者相比,CRi患者PFS的HR为2.3(95% CI: 1.3-3.9; P = .002)。
- 在CR患者中,MRD阳性与MRD阴性患者PFS的HR为1.85(95% CI: 0.9-4.0; P = .1)。
- 在CR患者的多变量分析中,仅年龄可预测结局,移植时MRD状态不影响治疗结局。
临床怎么用
- MRD阳性AML患者可考虑尽快进行haplo-SCT,因未显示对移植结局有负面影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There have been conflicting results regarding the impact of minimal/measurable disease at transplant on acute myeloid leukemia (AML) outcomes after haploidentical transplantation (haplo-SCT). We assessed the impact of pre-transplant disease status on post-transplant outcomes of 143 patients treated with haplo-SCT using fludarabine-melphalan (FM) conditioning and post-transplant cyclophosphamide (PTCy). With a median follow-up of 29 months, the two-year PFS for all patients was 41%. Compared to patients in complete remission (CR) at transplant, those with active disease (n = 29) and CR with incomplete count recovery (CRi) (n = 39) had worse PFS. They had hazard ratios (HR) of 3.5 (95% CI: 2.05-6.1; P < .001) and 2.3 (95% CI: 1.3-3.9; P = .002), respectively. Among patients who were in CR at transplant, there were no differences in PFS between those who had minimal residual disease (MRD) positive (n = 24), and MRD negative (n = 41) (HR 1.85, 95%CI: 0.9-4.0; P = .1). In multivariable analysis for patients in CR, only age was predictive for outcomes, while MRD status at transplant did not influence the treatment outcomes. Our findings suggest that haplo-SCT with FM conditioning regimen and PTCy-based GVHD prophylaxis has a protective effect, and may potentially abrogate the inferior outcomes of MRD positivity for patients with AML. Patients with positive MRD may benefit from proceeding urgently to a haplo-SCT, as this does not appear to negatively impact transplant outcomes.
引用
- Srour SA, Saliba RM, Bittencourt MCB, et al. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019. PMID: 31595538. doi:10.1002/ajh.25647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。